JP7555270B2 - Ｔｒｅｇ細胞を標的とするための方法及び組成物 - Google Patents

Ｔｒｅｇ細胞を標的とするための方法及び組成物 Download PDF

Info

Publication number
JP7555270B2
JP7555270B2 JP2020564822A JP2020564822A JP7555270B2 JP 7555270 B2 JP7555270 B2 JP 7555270B2 JP 2020564822 A JP2020564822 A JP 2020564822A JP 2020564822 A JP2020564822 A JP 2020564822A JP 7555270 B2 JP7555270 B2 JP 7555270B2
Authority
JP
Japan
Prior art keywords
antibody
neo
cancer
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512965A5 (https=
JP2021512965A (ja
Inventor
アーレン、フィリップ、エム．
ツァン、クウォン、ワイ．
デイビッド、ジャスティン、エム．
ファンティーニ、マッシモ
Original Assignee
プレシジョン バイオロジックス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレシジョン バイオロジックス、インコーポレイテッド filed Critical プレシジョン バイオロジックス、インコーポレイテッド
Publication of JP2021512965A publication Critical patent/JP2021512965A/ja
Publication of JP2021512965A5 publication Critical patent/JP2021512965A5/ja
Priority to JP2024155435A priority Critical patent/JP2024177188A/ja
Application granted granted Critical
Publication of JP7555270B2 publication Critical patent/JP7555270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020564822A 2018-02-13 2019-02-13 Ｔｒｅｇ細胞を標的とするための方法及び組成物 Active JP7555270B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024155435A JP2024177188A (ja) 2018-02-13 2024-09-10 Ｔｒｅｇ細胞を標的とするための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630084P 2018-02-13 2018-02-13
US62/630,084 2018-02-13
PCT/US2019/017870 WO2019160970A1 (en) 2018-02-13 2019-02-13 Methods and compositions for targeting treg cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024155435A Division JP2024177188A (ja) 2018-02-13 2024-09-10 Ｔｒｅｇ細胞を標的とするための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2021512965A JP2021512965A (ja) 2021-05-20
JP2021512965A5 JP2021512965A5 (https=) 2022-02-17
JP7555270B2 true JP7555270B2 (ja) 2024-09-24

Family

ID=67619085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564822A Active JP7555270B2 (ja) 2018-02-13 2019-02-13 Ｔｒｅｇ細胞を標的とするための方法及び組成物
JP2024155435A Pending JP2024177188A (ja) 2018-02-13 2024-09-10 Ｔｒｅｇ細胞を標的とするための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024155435A Pending JP2024177188A (ja) 2018-02-13 2024-09-10 Ｔｒｅｇ細胞を標的とするための方法及び組成物

Country Status (9)

Country Link
US (2) US12037410B2 (https=)
EP (1) EP3752533A4 (https=)
JP (2) JP7555270B2 (https=)
CN (1) CN112041343B (https=)
AU (2) AU2019221544B2 (https=)
BR (1) BR112020016374A2 (https=)
CA (1) CA3091181A1 (https=)
MX (2) MX2020008415A (https=)
WO (1) WO2019160970A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246066A2 (en) * 2021-05-19 2022-11-24 Precision Biologics, Inc. Methods and compositions for treating hematological malignancies
CN114010803B (zh) * 2021-11-30 2023-04-07 广东省人民医院 一种检测活体肿瘤微环境中Treg细胞的多功能靶向分子探针及其应用
AU2023272108A1 (en) * 2022-05-19 2024-11-07 Precision Biologics, Inc. Methods for ablating myeloid derived suppressor cells using neo-201 antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017123851A (ja) 2007-11-08 2017-07-20 ネオジェニックス オンコロジー， インコーポレイテッド 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010A (en) 1841-03-18 Machine foe
US4810781A (en) 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
USRE39760E1 (en) 1988-03-31 2007-08-07 International Bio-Immune Systems Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5688657A (en) 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP1320551A4 (en) 2000-09-01 2006-12-20 Internat Bioimmune Systems Inc IDENTIFICATION AND DEVELOPMENT OF SPECIFIC MONOCLONAL ANTIBODIES AGAINST SQUAFTEPITHELIC CARCINOMA
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
US8277804B2 (en) * 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US20120064100A1 (en) 2009-03-18 2012-03-15 Simon Barry Biomarkers and uses thereof
WO2011139738A2 (en) * 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
ES2719624T3 (es) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomiméticos de cáncer de colon y de páncreas
WO2012075111A1 (en) * 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
JP2013059295A (ja) * 2011-09-14 2013-04-04 Nagoya City Univ ｓｉＲＮＡ、抗原提示細胞、制御性Ｔ細胞及び治療薬
CN105188749B (zh) * 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
CA2896723C (en) 2012-12-28 2024-02-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2014319921A1 (en) * 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
PE20171790A1 (es) * 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
US11279768B1 (en) * 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
EP3295171A1 (en) * 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
KR20190017735A (ko) * 2016-04-07 2019-02-20 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
WO2018218230A1 (en) * 2017-05-26 2018-11-29 Etubics Corporation Combination immunotherapies comprising il-15 superagonists
WO2019090134A1 (en) * 2017-11-03 2019-05-09 Precision Biologics, Inc. Monoclonal antibody neo-201 for the treatment of human carcinomas
WO2020018425A1 (en) * 2018-07-16 2020-01-23 Nantcell, Inc. Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017123851A (ja) 2007-11-08 2017-07-20 ネオジェニックス オンコロジー， インコーポレイテッド 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2018年，Vol.8, Article 1899，pp.1-14
Journal of Clinical Oncology，2016年02月01日，Vol.34, No.4，suppl (February 01,2016) 500

Also Published As

Publication number Publication date
AU2019221544B2 (en) 2025-07-10
AU2025248631A1 (en) 2025-10-30
WO2019160970A1 (en) 2019-08-22
US20210002383A1 (en) 2021-01-07
CN112041343B (zh) 2024-08-30
AU2019221544A1 (en) 2020-10-01
MX2025010847A (es) 2025-10-01
MX2020008415A (es) 2020-10-28
JP2024177188A (ja) 2024-12-19
BR112020016374A2 (pt) 2020-12-15
EP3752533A4 (en) 2021-05-05
US12037410B2 (en) 2024-07-16
CA3091181A1 (en) 2019-08-22
US20240400714A1 (en) 2024-12-05
JP2021512965A (ja) 2021-05-20
CN112041343A (zh) 2020-12-04
EP3752533A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
JP7712338B2 (ja) ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
US20230190796A1 (en) Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US20240400714A1 (en) Methods and compositions for targeting treg cells
US20190358262A1 (en) Methods for modulation of car-t cells
US20230348620A1 (en) Chimeric antigen receptors specific for p95her2 and uses thereof
CA3083467C (en) Monoclonal antibody neo-201 for the treatment of human carcinomas
US20240384003A1 (en) Methods and compositions for treating hematological malignancies
Harrasser ROR1-targeted adoptive immunotherapies
HK40112663A (zh) 用於治疗血液恶性肿瘤的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240910

R150 Certificate of patent or registration of utility model

Ref document number: 7555270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150